clinical trial · NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Diffuse Large B-cell LymphomaMantle Cell LymphomaAbexinostatIbrutinib
brief summary
The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.
started
May 29, 2019
primary completion
Apr 22, 2025
completion
Apr 22, 2025
last updated
Apr 25, 2025
official title
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol